Tirzepatide trials for Obesity

All Tirzepatide trials · All Obesity trials

Phase breakdown

Recruiting trials studying Tirzepatide for Obesity

• 2024 Tirzepatide-Bariatric Surgery
  NCT06721507 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar
  NCT07284511 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
  NCT06700538 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 7 locations
• A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
  NCT06143956 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 56 locations
• A Study of BGM0504 in Participants With Obesity
  NCT06911203 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
  NCT07247084 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
  NCT06439277 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · 69 locations
• A Study of a Weight Loss Intervention in People With Endometrial Cancer
  NCT06751589 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: Female · 7 locations
• A Study to Evaluate ALN-2232 in Participants With Obesity
  NCT07463846 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
  NCT06864026 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 55 locations
• A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
  NCT06857942 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 39 locations
• A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults
  NCT07364175 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 40 Years · Sex: All (male and female) · 2 locations
• Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
  NCT07309094 · Phase: Not specified · Ages: 18 Years to 90 Years · Sex: All (male and female) · 1 location
• Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis
  NCT07443956 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 4 locations
• Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity
  NCT05933499 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
  NCT06934642 · Phase: Early Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults
  NCT06811324 · Phase: Phase 2 · Ages: 50 Years and older · Sex: All (male and female) · 1 location
• Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes
  NCT07521631 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
  NCT07481747 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
  NCT06847399 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• GLP-1R Actions on Muscle and the Skeleton
  NCT07154719 · Phase: Phase 4 · Ages: 18 Years to 50 Years · Sex: All (male and female) · 2 locations
• Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
  NCT06582875 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Incretin Therapies in Obesity-related HFpEF
  NCT07554638 · Phase: Phase 4 · Ages: 40 Years and older · Sex: All (male and female) · 2 locations
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
  NCT06937086 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 374 locations
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
  NCT06937099 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 183 locations
• Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
  NCT07095517 · Phase: Phase 1 · Ages: 18 Years to 50 Years · Sex: All (male and female) · 1 location
• Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity
  NCT07245771 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
  NCT06759701 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
• Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity
  NCT07228741 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity
  NCT07293325 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)
  NCT06191848 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
  NCT06802081 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity
  NCT07218445 · Phase: Phase 4 · Ages: 46 Years to 60 Years · Sex: Female · 1 location
• The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease
  NCT06606821 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Tirzepatide (Spartina) in Obese Kidney Transplant Recipients
  NCT07423247 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Tirzepatide Use in People With Obesity and Type 1 Diabetes
  NCT07096908 · Phase: Phase 4 · Ages: 21 Years and older · Sex: All (male and female) · 1 location
• Tirzepatide Weight Loss for MRD+ Early Breast Cancer
  NCT06517212 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Tirzepatide and Muscle Outcomes in Obesity
  NCT07373834 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 50 Years · Sex: Female · 1 location
• Tirzepatide for Alcohol Use Disorder
  NCT06994338 · Phase: Phase 2 · Ages: 21 Years to 65 Years · Sex: All (male and female) · 1 location
• Tirzepatide in Obesity-Driven Endometrial Cancer
  NCT07065552 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: Female · 1 location
• Tirzepatide in PWS, HO and GNSO
  NCT06901245 · Phase: Phase 4 · Ages: 18 Years to 26 Years · Sex: All (male and female) · 3 locations
• Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
  NCT07257484 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Female · 2 locations
• Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
  NCT05912621 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location

Common questions

How many trials study Tirzepatide for Obesity?

43 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.